Skip to main content

Care

By Susan Morse | 01:55 pm | February 12, 2026
Amazon is competing with Walmart in the delivery business and against pharmacies such as CVS and Walgreens.
Emerging Technologies
By Jessica Hagen | 01:40 pm | February 12, 2026
Dr. Amit Zabtani, cofounder and CMO of CustoMED and orthopedic surgeon at UCLA, joins MobiHealthNews to discuss 3D printing personalized surgical instruments.
By Jessica Hagen | 12:02 pm | February 12, 2026
The doctor quality analytics company's total funding to date is around $200 million.
Emerging Technologies
By HIMSS TV | 09:47 am | February 12, 2026
Dr. Amit Zabtani, an orthopedic surgeon at UCLA and cofounder and CMO of CustoMED, says the company uses 3D printing to create patient-specific instruments based on an individual’s anatomy, enabling more precise positioning during surgery.
By Jessica Hagen | 10:20 am | February 11, 2026
New York-based Somethings will use the funds to scale its mobile app that connects teens and young adults with trained peer mentors.
By HIMSS TV | 10:09 am | February 11, 2026
According to Clearwater's Jackie Mattingly, sustainable cybersecurity funding for rural hospitals remains elusive, with many states allocating little to no Rural Health Transformation Program money to security.
By Jessica Hagen | 08:00 am | February 11, 2026
The partnership will allow Mira's hormone test results to be compared with Oura Ring data on sleep, temperature and readiness, enabling trend tracking.
By Adam Ang | 07:35 pm | February 10, 2026
A community trial has shown that the data-driven, fall-detecting wearable robot developed at Nanyang Technological University requires less physiotherapist assistance.
By Jessica Hagen | 04:33 pm | February 09, 2026
The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain barrier to help treat neurodegenerative diseases.
By Jessica Hagen | 01:40 pm | February 09, 2026
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.